Mononuclear cells (MNCs) containing peripheral blood stem cells (PBSCs) were obtained from solid-tumor patients undergoing mobilizing chemotherapy followed by granulocyte colony-stimulating factor for PBSC transplantation-supported dose-intensified anticancer chemotherapy and were transplanted into unconditioned "nonleaky" young severe combined immunodeficient mice. Multilineage engraftment was shown by flow cytometry and immunocytochemistry using monoclonal antibodies to various human cell surface antigens as well as identification of human immunoglobulin in murine sera. Within a dose range of MNCs suitable for transplantation (10 to 36 x 10' cells/graft) the number of CD34+ cells injected (optimal at > 0.7 x lO'/graft) determined the yield of human cells produced in recipient animals. Engraftment of hu PBSC preparations resulted in prolonged generation of physiologic levels of human cytokines including interleukin-3 (IL-3). IL-6, and granulocyte-VER THE PAST YEARS there has been a substantial progress in the use of peripheral blood stem cells (PBSCs) after myeloablative chemotherapy for chemosensitive malignancies, thereby allowing for rapid, complete, and sustained hematopoietic recovery.',' Marrow suppressive chemotherapy followed by administration of hematopoietic growth factors3-' is predominantly used for mobilization of PBSCs resulting in a rapid increase of circulating blood cell progenitors, which also include primitive stem cells. 6 The prediction of successful engraftment and long-term hematopoietic reconstitution is of major relevance in stem cell transplantation. As has been shown in mice, engraftment develops throughout two distinct phases with the first being brought about by committed progenitors and the second sustained phase being established by pluripotent stem cells.' To date, the peripheral pluripotent hematopoietic stem cell present in the PBSC graft and capable of reconstituting long-term hematopoiesis is still poorly characterized. In particular, it remains to be established to what extent the mobilization schedule andor the release of early stem cells from their regulatory bone marrow (BM) microenvironment into the circulation affects the preservation of their replicative potentiaL8 One legitimate concern regarding the use of PBSCs for transplantation after myeloablative chemotherapy was late BM failure.' This has been addressed, at least in part, by experiments designed to show that granulocyte colony-stimulating factor (G-CSF) treatment was capable of increasing the frequency and self-renewal capacity of primitive stem cells in murine blood."." Whether exposure of the peripheral pluripotent stem cell to growth factors, as used in ex vivo expansion protocols using appropriate cytokine combination~,'*"~ induces predominantly maturational divisions, eventually leading to an exhaustion of the stem cell pool, remains a matter of debate. With the application of PBSC transplantation to a broader range of neoplastic disorders, the risk of contamination of the PBSC sample with tumor cells was observed to be higher than e~pected.""~ Recent
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Blood, V01 86, No 1 (July l), 1995: pp 89-100 macrophage colony-stimulating factor, which were detectable in the murine blood over a period of at least 4 months. In vivo survival of immature human progenitor cells was preserved even 9 months after transplantation. Because human IL-3 is known to stimulate early hematopoiesis, a rat fibroblast cell line was stably transfected with a retroviral vector carrying the human IL-3 gene and cotransplanted subcutaneously as additional source of growth factor. Cotransplants of this cell line producing sustained in vivo levels of circulating human IL-3 for at least 12 weeks significantly accelerated the process of engraftment of huPBSC and spurred the spread of mature human cells to the murine spleen, liver, thymus, and peripheral blood. Cotransplants of allogeneic human bone marrow stromal cells derived from long-term cultures resulted in a comparable-though less prominent-support of engraftment. 0 1995 by The American Society of Hematology.
reports underline the risk of tumor cell mobilization in patients with malignant BM involvement.20-zz Because gene marker studies have not definitively ruled out the possible involvement of reinfused tumor cells in disease relap~es,'~ efficient procedures to eliminate contaminating tumor cells from PBSC preparations will be needed to prevent their reinfusion with the leukapheresis This, again, raises the question whether any purging protocols used to eradicate contaminating tumor cells from the graft would affect the primitive hematopoietic stem cells and whether a stem cell reserve will be actually established by the transplant. Therefore, development of an animal model to experimentally address these questions is expected to give clinically relevant information.
Several groups have used xenogeneic BM transplantation into immunodeficient mice to study human hematopoiesis. Some of the models require surgical implantation of human fetal liver and thymus26 or human fetal bone fragments." Recently, a different system has been described that allowed successful engraftment of adult human BM.28 In this model, unfractionated human BM cells were transplanted into irradiated severe combined immunodeficient (SCID) mice. Human hematopoiesis was spurred in these animals by recombinant human cytokines injected intraperitoneally at 48-hour intervals during the engraftment period.
To examine individual PBSC transplants for early hematopoietic stem cells and their replicative potential, we have attempted to establish a SCID-human (hu) PBSC mouse model by grafting mononuclear cells from cytapheresis products (CP) to young "nonleaky" SCID mice.29 We show that CD34+ human stem cells present in these grafts are readily able to home to the SCID mouse BM, where the murine hematopoietic microenvironment may support their proliferation and differentiation into precursors of the myeloid and lymphoid lineages. The in vivo survival of primitive human progenitor cells was preserved over a period of at least 9 months. Engraftment of human PBSC preparations resulted in continuous generation of physiologic levels of human cytokines including IL-3, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) measurable in the murine blood over a period of at least 4 months. As additional sources of human cytokines, subcutaneous cotransplants of either human BM stromal (BMS) cells derived from longterm cultures or a rat cell line stably transfected with the human IL-3 gene were instrumental. Both types of cotransplants were capable of accelerating the engraftment process and promoted the spread of mature human cells to the murine spleen, liver, thymus, and circulation.
MATERIALS AND METHODS
Peripheral blood stem cells. Mononuclear cells (MNCs) were obtained from the CPs collected from 6 sequential patients undergoing PBSC transplantation including 3 patients with metastatic breast cancer (MBC), 2 patients with nonseminomatous testicular cancer (NSTC), and 1 patient with epithelial ovarian cancer (EOC). All patients were Epstein-Barr virus-negative by serologic means. The protocol for stem cell mobilization for each patient is shown in Table  I . Twenty-four hours after discontinuing mobilization chemotherapy, 5 pg/kg G-CSF (Neupogen; Amgen, Thousand Oaks, CA) was given until the last day of stem cell sampling (usually two collections per patient). Cytapheresis was performed using continuous flow devices (Fenwal CS 3000; COBE spectra) on 2 to 3 consecutive days. when leukocyte and platelet counts had reached 3 and 50 X IO'/L of blood, respectively. Ten to 15 L of blood processed each time yielded a 100-fold concentrated CP. 30 The MNC from 3-mL samples of freshly collected CP were washed and resuspended in phosphatebuffered saline (PBS). Samples were drawn for flow cytometry and for hematopoietic progenitor assay ( Table 2) .
Transplantation of PBSC into SCID mice. CB-l7 scidscid mice were obtained from the Bundesgesundheitsamt (Berlin, Germany) and were maintained under pathogen-free conditions in the animal facility of the Max-Delbriick-Center for Molecular Medicine (Berlin, Germany). They were housed in laminar-flow cabinets and were given autoclaved food and bedding (Sniff, Soest, Germany) and acidified drinking water of pH 4. The environmental conditions were set to 24 to 26°C room temperature, 50% relative humidity, and 12-hour light-dark rhythm. Only unconditioned 4-to 5-week-old "nonleaky" mice (murine Ig <50 ng/mL of serum) were used in these experiments. Usually 1 to 4 X 1 O7 cells from samples of fresh CP were resuspended in 0.2 mL of PBS and injected intraperitoneally into each animal.
Cytokine-producing cotransplants.
As indicated in Results, in some experiments a rat fibroblast cell line stably transfected with the human interleukin-3 (huIL-3) gene, Rat-huIL-3 clone IOA, was cotransplanted with the PBSCs. To obtain a cell line producing high titers of huIL-3, the Ratl fibroblast cell line" was infected with a huIL-3-expressing retroviral vector. The pM5huIL-3 plasmid DNA contains a MPSV-based M5neo retroviral vector"." expressing the huIL-3 gene24 and was kindly provided by C. Stocking (HeinrichPette-lnstitut, Hamburg, Germany). Ten micrograms of pM5huIL-3 plasmid DNA was transfected into GP+envAM12" cells by electroporation.36 After 48 hours, cells were selected in the presence of 0.4 mg/mL of G418 and individual clones were picked after 12 to 14 days. Supernatants from clones releasing relatively high virus titer were used to infect Rat1 cells to establish stably transfected hulL-3-producing cell lines. After 14 days in selection medium, the neoresistant Rat1 clones were expanded and examined for release of biologically active huIL-3 using the human factor-dependent TF-I cell line" as an indicator cell line. Supernatants from confluent RathuIL-3 were collected after 24 hours and added at various dilutions to microwell cultures of TF-I cells in Terasaki plates. TF-I cells were washed three times with Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal calf serum (FCS) (ie, no IL-3 ) before plating at 2 X 10' cells per well. After 3 days of culture, the number of cells per well was enumerated. Assays were performed in triplicates and each supernatant was assessed in three independent experiments. Half-maximal stimulation of TF-l cells with recombinant IL-3 was achieved with 1 U/mL. Twenty two to one hundred sixty-seven U/mL huIL-3 were secreted by the different clones. Clone IOA, which secreted about 100 U/mL hulL-3. was used throughout this study. To exclude virus release from the Rat-huL 3 cells, supernatants of several huIL-3-secreting clones were analyzed for viral particles by titration on uninfected Ratl cells and by a reverse-transcriptase assay." No virus release was detected from all Rat-huIL-3 cell lines repeatedly analyzed.
Human long-term BM cultures (LTBMCs) were set up using filterretained material from BM samples of consenting allotransplant donors and cultured in LTBMC medium (Terry Fox Labs, Vancouver, BC) for several weeks. The stromal cells were subpassaged at least three times to form confluent monolayers of mainly fibroblastoid morphology.
Both cell types used for cotransplantation were propagated in Iscove's modified Dulbecco medium (IMDM; GIBCO BRL, Gaith- Data were recorded by flow cytometry analysis and hematopoietic progenitor assay. Abbreviations: CFU-C, colony-forming unit; ND, not determined. *Average number (+SD) of colony-forming units assessed on the day of MNC use for grafting.
ersburg, MD) supplemented with 10% (voVvol) FCS (GIBCO BRL).
Trypsinized cells were washed and resuspended in 0.5 mL. of culture medium without additives, cooled down to 4°C and mixed with matrigel (Basement Membrane Matrix 40234, Becton-Dickinson, Bedford, MA) using precooled pipettes to avoid gelling. The matrigel stock solution (10.8 mg/mL in DMEM) had been aliquoted in 0.5-mL portions that were kept frozen at -20°C. Appropriate amounts were thawed directly before mixing with an equal volume of cell suspension and kept at 4°C. Four to 5 X lo6 cells in 0.25 mL per mouse and were injected subcutaneously into the lateral abdomen using precooled needles and glass syringes. Quantitation of human and murine Ig levels. Venous blood was collected by puncture of the lateral tail vein of transplanted mice and total human Ig in the serum was measured with a standard double-antibody enzyme-linked immunosorbent assay (ELISA) starting 4 weeks after transplantation. Microtiter plates (Maxisorb, Nunc, Roskilde, Denmark) were coated with affinity-purified polyvalent rabbit antibodies to human Ig (10 pg/mL) (Sigma I 8010; Sigma Chemical CO, St Louis, MO) at 4°C overnight. Nonspecific binding of protein was eliminated by incubation with phosphate buffer containing 10% (voVvol) inactivated FCS and 0.1% (voVvol) Tween 20. Serial dilutions of mouse serum samples in the buffer were then incubated in duplicates for 2 hours at room temperature. Serial dilutions of affinity-purified human IgG (Sigma 1-2511) were included as controls to establish a standard curve for each plate. Pooled normal SCID serum was used as a negative control. After three washes, the wells were incubated with peroxidase-conjugated rabbit antibodies to human Ig (IgG, IgM, IgA) cross-absorbed to mouse Ig (Sigma A-8794). After additional washes, ortho-phenylene diamin (OPD, DAKO S 2000) in citrate buffer (pH 5 ) was added as the substrate solution and the optical density was determined using a Titertek Multiscan 212 (ICN, Meckenheim, Germany). Readings corresponding to values of greater than 10 ng/well were recorded as positive (ranging from 30 ng/mL to 300 pg/mL).
For analysis of murine Ig, microplates were prepared similar to those for human Ig using rabbit antibodies to mouse Ig cross-absorbed to human and bovine Ig (DAKO Z 259, Dakopatts A / S , Glostrup, Denmark) for coating and peroxidase-conjugated rabbit antibodies to mouse Ig (DAKO P 260) as the second antibody. Identical incubation times, washes and substrate were used. Purified mouse IgG (Dianova) was included for the standard curve. Readings corresponding to values greater than 1 ng/well were recorded as positive (range, 10 ng/mL to >3 pg/mL). The upper limit of murine Ig for the exclusion of "leakiness" in SCID mice used for grafting was considered to be below 50 ng/mL.
Measurement of human cyfokines. The human cytokines interleukin-3 (huIL-3), interleukin-6 (huIL-6), and huGM-CSF were quantitated both in huPBSC SCID mouse sera and in culture supernatants obtained after incubating the MNC from individual CP in LTBMC medium: IMDM (GIBCO BRL) supplemented with 10% FCS, 10% horse serum (GIBCO BRL), 5 X 10" m o m hydrocortisone sodium hemisuccinate (Sigma), penicillin, and streptomycin according to Demuynck et for 24 hours. In selected experiments, levels of huIL-lp, huIL-2, huIL-7, and huG-CSF were also determined. Commercially available ELISA kits for huIL-lP (DianovaImmunotech, Hamburg, Germany), huIL-2, huIL-3, huIL-7, huG-CSF (Quantikine; R & D Systems, H. Biermann Diagnostika, Bad Nauheim, Germany), huIL-6, and huGM-CSF (EndogenBiomar Diagnostic Systems, Marburg, Germany) were used according to the guidelines of the manufacturers. Sera of untransplanted young "nonleaky" SCID mice served as negative controls.
Cell preparation f o r j o w cytometry analysis. Mice were killed by cervical dislocation at the time points indicated. Their blood, spleens, livers, lungs, thymi, BM cells, and peritoneal cells washed out with 1 mL of PBS were collected for analysis. In most experiments the subcutaneously transplanted Rat-huIL-3 fibroblasts formed slow-growing, palpable tumors that were excised and minced. Single-cell suspensions were prepared and their cell numbers were determined by counting in a Neubauer hemocytometer by light microscopy. For erythrocyte lysis, murine blood samples or samples of the individual CP used for grafting were diluted with 14 volumes of a lysis buffer (NH,Cl 0.17 mol/L, KHCO? mom, EDTA m o w in aqua destillata, pH 7.3) and, after gentle mixing, kept at room temperature for 2 to 3 minutes.
Cell staining andjow cytometry. Cell suspensions were washed in PBS containing 0.1% bovine serum albumin (BSA; Sigma A 9418) and 0.1% NaN, (PBSiBSA) and, after a 10-minute preincubation with PBSiBSA plus 10% normal mouse serum (Dianova), incubated for 30 minutes at 4°C with saturating concentrations of humanor mouse-specific monoclonal antibodies (MoAbs) conjugated with either fluorescein isothiocyanate (FITC) or phycoerythrin (PE) and washed two times thereafter. Anti-CD45 (Immunotech) was used to identify cells of human origin. B cells were detected by staining with anti-CD19 (DAKO). T cells were stained with anti-CD2 (Medac, Hamburg, Germany), anti-CD3 (Medac), anti-CD4 (DAKO), and anti-CD8 (DAKO). Natural killer (NK) cells were stained with anti-CD56 (Medac). Cells from the BM, thymus, spleen, and, in some experiments, from liver, lungs, and subcutaneous transplant sites were screened for human myeloid, erythroid, and lymphoid precursors with anti-CD33 and anti-CD13 (Immunotech), anti-CD16 (Medac), anti-CD38 (Becton Dickinson), anti-glycophorin A (Immunotech), and anti-HLA-DR (Medac) MoAbs. Immature cells were identified with an anti-CD34 MoAb (HPCA-2, Becton Dickinson). Murine cell surface antigens were stained with rat-antimouse Thy-l .2 (Medac), rat-antimouse Ly-5 (Medac), rat-antimouse CD45, and mouse-antimouse NK 1.1 (Pharmingen, Berlin, Germany). In some experiments antihuman CD45 MoAb conjugated with PeCP (Becton Dickinson) or antihuman HLA-DR and antihuman CD56 Tricolor MoAbs (Medac) were used to perform three-color flow cytometry analysis. In each experiment, cells from a "nonleaky" SCID mouse not transplanted with huPBSC were stained with the same antibodies as a negative control. To assess nonspecific fluorescence, isotype-matched antibodies conjugated with FITC or PE were also included. Cell analysis was performed with FACScan (Becton Dickinson) using Lysys I1 software. Each measurement contained 10 X Io" cells. In a two-color analysis, dead cells were excluded by propidium iodide staining.
Hematopoietic progenitor assay. MNCs from the individual CP were washed and resuspended in IMDM and plated to 0.5 to I X IO5 cells/mL in semisolid culture medium containing 0.9% methylcellulose, 1% BSA, 30% FCS, I X molL 2-mercaptoethanol, 2 X lo-' mol&, l-glutamine (GIBCO BRL), 1 X molL hemin (bovine hemin type I, cristalline, Sigma H2250), 2 U/mL human erythropoietin, 10 ng/mL recombinant huIL-3, and 20 U/mL huGM-CSF as human hematopoietic growth factors. The cultures were incubated at 37°C in an atmosphere of 95% humidity with 5% CO, in air. After 10 to 14 days, cultures were scored by morphologic criteria for GM-colony-forming unit (CFU), macrophage (M)-CFU, and G-CFU, for the erythroid (E) BFU or CFU and the multilineage colony-forming unit (CFU-GEMM). Blast-colony forming progenitors were not detected until day 21 of culture as confirmed by morphologic analysis using Wright-Giemsa-stained cytospins of picked colonies.
Histologic and cytologic analysis. Selected cases tissue pieces from the inner peritoneal lining of grafted mice that had been spread, air-dried, and acetone-fixed on prepared slides were examined immunohistochemically using a commercially available streptavidin-biotin peroxidase kit (LSABR 2, DAKO) with antihuman CD1 I C (DAKO) as primary antibody. Peroxidase activity was shown with aminoethyl carbazol. The tissue pieces were counterstained with hematoxylin. Immunocytochemical staining of BM cells bound to Alcian green spots on multispot slides was performed by a standard immune peroxidase protocol with antibodies specific for the human cell surface antigens mentioned above.
RESULTS

PBX-initiated human hematopoiesis in SCID mice.
Young "non-leaky'' SCID mice intravenously transplanted with human PBSC-containing MNCs developed symptoms resembling those of "discordant human xenogeneic graft versus host d i~e a s e "~' ,~' and died within 9 weeks posttransplantation (not shown). In contrast, intraperitoneally applied grafts were readily accepted, resulting in a sustained production of human Igs (mean, 90.6 ? 86.9 pg/mL of mouse serum, range, 0.03 to 309 pg/mL). As shown in Fig l, trans- plantation of 10 to 36 X lo6 MNCs from the CP of different patients resulted in successful engraftment over a period of at least 36 weeks posttransplantation. After 4 to 6 weeks, human cells were detectable by flow cytometry analysis in the chimeric BM, spleen, and circulation with their percentages increasing over the next 10 to 20 weeks. Human cells were also found to be retained at the transplantation site as well as in the murine thymus, lungs, and liver (not shown). After 24 weeks, in most of the animals the small SCID mouse thymus appeared fibrotic, lacking measurable amounts of human and murine lymphoid cells. Within an MNC dose range of 10 to 36 X lo6 cells per graft suitable for transplantation in our mouse model, the number of human CD34' stem cells injected (optimal at greater than 0.7 X 10' per graft) determined the yield of human cells produced in the recipients. Figure 2 shows the phenotypes of human hematopoietic progenitor cells found in the SCID mouse BM using twoand three-color flow cytometry analysis. The percentage of early CD34' HLA-DR. cells ranging from 0.S to 2.5 remained constant over the entire observation period. Myelomonocytic progenitors exhibiting the CD34TD33' (Fig 3) or CD33' phenotype only comprised the majority of engrafted cells, though a certain variability among the individual animals was observed. The presence of human CD34TD38' lymphoid precursors and CD19' B cells could also be shown in all animals indicating multilineage human hematopoiesis. Increasing amounts of CD34'CD 19' B-cell precursors (1% to 3%) appeared among the chimeric spleen cells and in the thymus 6 to 8 weeks posttransplantation, whereas only negligible amounts of human CD2+ T cells were found after 12 to 16 weeks (data not shown). Twentyfour weeks after transplantation, the total number of human hematopoietic BM cells moderately decreased, probably indicating a certain state of homeostasis as rather high levels of circulating human lymphocytes could be found after 6 to 9 months (Fig 1) .
Among the mature human lymphocytes, circulating CD19' B cells (Table 3 ) prevailed over time, whereas circulating T cells were rarely found. Eight to twelve weeks posttransplantation, human CD56' NK cells partially coexpressing CD16 and CD8 appeared in the circulation followed by CDIS' granulocytes and some glycophorin A' cells; low numbers of circulating CD3+CD4+/CD8' human T cells (greater than 1% to 2%) were found in some animals only. However, a distinct portion of human CD2'CD3-CD4""' human T cells became detectable in most of the murine blood samples tested 24 to 36 weeks posttransplantation. Figure 4 shows a representative sample collected from one of four SCID mice grafted with CP cells of patient 6 (see Table 1 ) and retained for a long-term follow-up.
Cytokine production of human P B X in vivolen vivo.
MNC samples of the individual CP used for grafting were incubated with long-term BM culture medium for 24 hours and release of various cytokines into the culture supernatant was assessed by specific ELISA. Figure 5A shows two representative experiments performed with fresh MNC from patients 4 and 6. In all experiments, IL-6 was found to be released in high concentrations, whereas only low quantities of G-CSF, M-CSF, GM-CSF, and IL-Ip were detectable. However, human IL-2 and IL-7 were not found. Upon grafting (Fig SB) , huPBSC gave rise to continuous long-lasting cytokine production in the recipients, indicating the presence of a cytokine-releasing donor cell type. By flow cytometry analysis of cells separated from various tissues and organs including spleen, liver, thymus, and peripheral blood we failed to detect populations of human T cells or human macrophages likely to be responsible for cytokine release. However, the rather crude methods used in preparing single-cell suspensions might be inappropriate to save tissue-adhering macrophages. Inguinal, axillary, or periportal lymph nodes, hardly discernible macroscopically in normal SCID mice, were never found to be enlarged. Analysis of immunoperoxi- d u e stains of the inncr pcritoneal lining using antihuman CD1 I C as primary antibody suggests that human macrophages might have scttled down at the transplantation site.
Human ll,-3, L-6, and GM-CSF were mcasurable i n a l l sera of grafted mice over a period of a t least 12 wceks, whereas low titers of G-CSF and IL-Io could be detected in a few casts only (data not shown). Again, hulL-2 or IL-7 were never found in any of the serum samples screened.
Etw1ogenorl.v .supplF of'humutz cytokinc.s in SCID-huPBSC
micr. In contraht with transplants of unfractionated adult human BM, which rcquire exogenous cytokincs for engraftment in SClD mice, the xcnotransplant model described here did not rcquire exogenous cytokinc supply for engl-aftment of human cells. Because clinical trials have shown thc cfficacy o f exogenously applied hematopoietins t o stimulate progenitor cell engraftment, WC sought to determine whether supply of a human hematopoietin like IL-3, known to lack cross-reactivity in the murine system, would accelerate the human bernntopoiesis in our chimeras. To this cnd, a rat fibroblast ccll line was stably transfccted with the human L 3 gene and used as cotransplant. Upon subcutaneous transplantation into normal SCID mice, this cell line was shown to produce 10.8 t 8.8 ng huIL-YmL (range, 0.6 to 22.5 ng/ml,, n = S) 01' mouse scrum after 7 to X weeks I.~osttransplantation. Cotransplants o f this ccll line should bc capable of sustaining a continuous physiologically relevant lcvcl or human 1L-3 in huPKSC SCID mice over a period of at least 2 months, thus obviating the need for repeated cytokine injcctions. In most cascs, the matrigel-clotted cytokine tumors showcd slow but progressive growth and wcrc always found to be vascularized and populated by human CD45 and CD34' cells as wcll as by murine granulocytic and monocytic cclls (not shown). Figure 6A shows the rcsults of these expcriments. SClD mice grafted with human PRSC intraperitoneally reccivcd subcutaneous cotransplants of Rat-huIL-3 cells on day 2. Individual mice were killed after 4, X. and 12 wceks and their BM cclls were analymd for thc presence of cells of human origin. Micc cngrafied with PRSC of the same donor and cotransplanted with Rat-I cells, which were transfected with a plasmid lacking the human L 3 gene, served as co11-trols. A continuous supply of hulL-3 clearly accelerated the production 01' human cclls by a factor of 4 to S after X weeks posttransplantation. Comparablc yields in unsupplclncntcd SCIII-huPBSC micc were reached only 4 to 8 wceks later. In both experiments ;I distinct fraction of human ClI34'ClI3X' K-lymphoid precursors (2% t o 6%) of total splenic lymphocytes), not sccn in mice cngralting huPBSC in (he absence o f human cytokines, c o~~l d be detected within the enlarged murine spleens and also, in one case, i n the enlarged thynnls.
As another source o f cytokines, hurnan BMS cells clcrivcd from LTBMC set up with filter-retained material from BM samplcs of two healthy allotransplant donors were used. These HMS cultures had previously been examined for i n vitro cytokine release over a period 01' I O to I2 weeks. BMS I'niled to sccretc IL-3, whereas low amounts o f ILIP, GM-CSF, and G C S F and rather high lcvcls o f L 6 (2 to 4 ng/ IO'' cells per day) became detectable in BMS culture supcrn;1-tants (data not shown). Grafted SCIII mice receiving KMS cotransplants and controls wcrc processed ;IS indicated above. As shown in Fig hB, the cotransplant of one of thc KM donors promoted the human hematopoiesis within the murine BM colnpal-ahly with Rat-hulL-3 cells, whereas the second BMS graft gave only marginal support. Surprisingly, with this latter cotransplant a distinct thymic population of human CD2' cells ( 5 % to 7% o f total cells) and slightly higher lcvcls of circulating human CDSh' N K cells, CDI9' B cells. antl CD I S ' granulocytes were found i n sonic of the SCIII recipients. These preliminary data have to be COIF tirmctl i n additional experiments using BMS grafts from different donors and/or established stromal cell lines 01 known cytokine production pattern for cotransplantation. It would also be desirablc t o add exogenous IL-2 to transplanted animals to sec if this technique promoted the dcvelopmetlt ofT cells. Thcsc cxpcriments are currently underway in o u r laboratory.
DISCUSSION
Human PUSCs rnobilized by chemotherapy and G-CSF can efficiently engraft young "nonleaky" SCIII mice resulting i n long-lasting multilineage hematopoiesis in the BM of recipients. Adult human KM has recently been shown to require the continuous presence o f ' human cytokines for successful engraftment.2x I n contrast, the 1nononuclcar cells contained in cytaphcrcsis products obtained after mobilization o f hematopoietic stem cells into the circulation are capable o f homing to the murine B M antl of initiating a human hematopoicsis for up to 9 months posttransplantatioll in the h e n c e o f exogenous human hematopoietic growth factors. Our data on production and release of various cytokincs by MNCs cultured in vitro o r transplanted into SCIII mice are in line with ;I report by Takarnatsu et al,42 which describes elevated cytokine levels i n supernatants of cultured MNCs as well as in patients' plasma collcctcd during the recovery phase after intensive chcmothcrapy. An in vivo activation o f monocytes and 'r cells during hematopoietic recovery as suggested by the relatively high proportion o f HLA-Dl<' MNCs found i n the CP used in our study (see Table 2 ) may account for successful engraftment of blood stem cells 
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collected after mobilizing treatment. This would also explain the more rapid hematopoietic reconstitution observed after reinfusion of PBSC as compared with autologous BM transplant~.~~," Because T-cell activation is accompanied by an increased avidity of cell adhesion molecules to their ligands broadly expressed on hematolymphoid and nonhematolymphoid tissues,45 strong cell-cell and cell-matrix adhesion and transmigration could be expected. This would explain, at least in part, why we were unable to identify circulating mature human T cells. We hypothesized that subpopulations of preactivated T cells present in the graft might have adhered to the peritoneal lining at the transplantation site or somewhere in lymphoid organs. Autocrine T-cell growth factors like IL-2, but also IL-7, which is readily bound by receptor-bearing cells in the close vicinity and, therefore, not detectable in murine serum, would then promote T-cell survival and amplification. With respect to their transplantability into SCID mice, PBSCs resemble human umbilical cord blood (CB) cells for which successful engraftment and initiation of a multilineage hematopoiesis has been shown in the absence of exogenous human ~y t o k i n e s .~~ Findings on the effective enhancement of colony formation in CB multipotential progenitor cell replating assays by CB plasma4' suggest cytokine release by CB lymphocytes. In grafting huPBSC preparations to SCID mice, within the optimal dose range, the percentage of human CD34+ stem cells and early progenitors was important. In comparison with the threshold dose of 1.5 to 5 X 10' GMCFUkg body weight estimated for a PBSC graft to establish complete and sustained hematopoietic recovery in humans:' the apparent threshold dose of greater than 5 X 10' cells/ graft found for SCID mice is about 50 times higher.
Flow cytometry analysis of the BM of engrafted mice showed repopulation with predominantly immature human cells of myeloid and lymphoid origin as well as mature However, the definite proof for an engraftment by the plurpotent human stem cell will require more work to determine the reliability of this assay in determining the relative frequency of human primitive cells.
Comparison of the engrafted cells in different organs showed substantial amounts of human B-lymphoid cells in the murine spleen, blood, and, in some cases, thymus, whereas mature human T cells were rarely found. Human NK cells, which appeared in the circulation after 2 to 3 months, were apparently generated from the engrafted progenitors and were mouse-educated, because we could not find any symptoms of cellular cytotoxicity in the animals. These observations are in line with recent reports on the rapid reconstitution of the B-cell and NK cell compartments after PBSC transplantation in human recipients5' The particular deficiency of human T-lymphopoiesis in our animal model could reflect a deficiency of the thymopoiesis-promoting cytokines like IL-2, shown to be essential for successful engraftment of allogeneic T cells in SCID mice:' or IL-4, and IL-7. This was confirmed by the absence of detectable levels of IL-2 or IL-7 either in PBSC culture supernatants or in the engrafted animals. Another possible obstacle to a chimeric human thymopoiesis is the rudimentary SCID mouse thymus, which has been shown to contain normally functioning antigen-presenting ~e l l s~~,~~ and to promote the differentiation of grafted normal allogeneic stem cells into functionally competent T lymphocyte^.^^ Recently, in an organ culture system using human CD34++ fetal liver stem cells and isolated thymic lobes of fetal SCID mice, in the presence of newly generated human HLA-DR+ cells that exhibited dendritic morphology, successful human thymopoiesis and T-cell maturation was ~bserved.~' Therefore, another prerequisite to xenogeneic human thymopoiesis in the adult SCID mouse would be a repopulation of the murine thymus with functional human dendritic cells and macrophages capable of secreting the lymphokines required a n d or expressing the relevant major histocompatibility complex (MHC) class I1 molecules. The small population of circulating CD2fCD3-CD4di" cells appearing late after transplantation might represent a fraction of early thymocytes already committed to the T-cell lineage but arrested at an immature stage before the rearrangement of T-cell receptors (TCR) had
In this respect, they resemble the immature thymocytes found in "nonleaky" SCID mice that are unable to undergo TCR rearrangement and, thus, are incapable of supporting a normal development of thymic medullary epithelium shown to be dependent on TCR+ lymphoid cells in a bidirectional symbiotic relati~nship.~~ Our results also show that multilineage human hematopoiesis in huPBSC-grafted mice can be accelerated and amplified by cotransplanted rat fibroblasts engineered to continuously secrete human IL-3 at physiologically relevant levels. hu PBSC SClD mouse serum (pg per ml)
Cotransplants of cultured BMS cells known to produce low (if any) levels of IL-3,60 but able to secrete a variety of other hematopoietic growth factors, including large amounts of IL-6, seem to promote the huPBSC-initiated hematopoiesis in an almost comparable fashion. Presumably, their efficiency depends on the cytokine production pattern of the BM stroma derived from individual donors. Appropriate mixtures of both cytokine-producing cell types for cotransplantation could then create a human hematopoietic microenvironment more suitable for purified stem cell transplants depleted of helper or facilitating cells that might contribute to differentiation induction or maintenance. The limited number of individual cytapheresis products tested so far does not yet allow for clinically meaningful statistical analysis. The quality of a PBSC preparation in terms of early stem cell and progenitor content is influenced by the number of myelosuppressive pretreatment protocols. However, in therapeutic decisions regarding the feasibility of PBSC mobilization and transplantation, multiple aspects should be taken into consideration. Our studies with PBSCs from patient no. 6, who had received five cycles of myelotoxic treatment, suggest that successful engraftment and long-lasting hematopoiesis may be accomplished by an otherwise intact adult human BM despite multiple pretreatment schedules.
In conclusion, our xenotransplant model may be useful in evaluating a PBSC transplant with respect to its content of hematopoietic stem cells and their capacity for self-renewal to reestablish a stem cell pool after reinfusion. It would also allow an evaluation of the efficacy of (1) different stem cell mobilization protocols and/or the influence of previous therapy protocols, (2) procedures for stem cell separation and tumor cell purging, and (3) an ex vivo expansion of early stem cells with respect to preservation of the selfrenewing and proliferative potential of HSC in vivo after transplantation. This will necessarily involve serial transplantations of SCID-huPBSC BM into lethally irradiated secondary recipients. These studies are now ongoing in our GOAN ET AL laboratory. Moreover, it could be useful in assessing the long-term expression of genes transduced to human HSC in gene transfer experiments designed for future gene-therapy protocols.
